Dynavax Technologies Corporation (DVAX)
NASDAQ: DVAX · IEX Real-Time Price · USD
11.54
-0.14 (-1.20%)
May 2, 2024, 12:55 PM EDT - Market open
Dynavax Technologies Revenue
In the year 2023, Dynavax Technologies had annual revenue of $232.28M, a decrease of -67.86%. Revenue in the quarter ending December 31, 2023 was $55.60M, a -69.87% decrease year-over-year.
Revenue (ttm)
$232.28M
Revenue Growth
-67.86%
P/S Ratio
6.57
Revenue / Employee
$569,324
Employees
408
Market Cap
1.51B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 232.28M | -490.40M | -67.86% |
Dec 31, 2022 | 722.68M | 283.24M | 64.45% |
Dec 31, 2021 | 439.44M | 392.89M | 844.00% |
Dec 31, 2020 | 46.55M | 11.33M | 32.18% |
Dec 31, 2019 | 35.22M | 27.02M | 329.60% |
Dec 31, 2018 | 8.20M | 7.87M | 2,407.03% |
Dec 31, 2017 | 327.00K | -10.72M | -97.04% |
Dec 31, 2016 | 11.04M | 6.99M | 172.67% |
Dec 31, 2015 | 4.05M | -6.98M | -63.29% |
Dec 31, 2014 | 11.03M | -219.00K | -1.95% |
Dec 31, 2013 | 11.25M | 1.54M | 15.82% |
Dec 31, 2012 | 9.71M | -11.90M | -55.06% |
Dec 31, 2011 | 21.61M | -2.34M | -9.75% |
Dec 31, 2010 | 23.95M | -16.37M | -40.60% |
Dec 31, 2009 | 40.32M | 3.22M | 8.69% |
Dec 31, 2008 | 37.09M | 23.00M | 163.21% |
Dec 31, 2007 | 14.09M | 9.25M | 190.76% |
Dec 31, 2006 | 4.85M | -9.81M | -66.93% |
Dec 31, 2005 | 14.66M | -157.00K | -1.06% |
Dec 31, 2004 | 14.81M | 13.99M | 1,693.22% |
Dec 31, 2003 | 826.00K | -601.00K | -42.12% |
Dec 31, 2002 | 1.43M | -932.00K | -39.51% |
Dec 21, 2001 | 2.36M | 305.00K | 14.85% |
Dec 31, 2000 | 2.05M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Warby Parker | 669.77M |
InMode | 492.05M |
ADMA Biologics | 258.22M |
LeMaitre Vascular | 193.48M |
Ardelyx | 124.46M |
Arcus Biosciences | 117.00M |
Protagonist Therapeutics | 60.00M |
DVAX News
- 7 days ago - Dynavax to Report First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024 - PRNewsWire
- 2 months ago - Dynavax to Present at TD Cowen's 44th Annual Health Care Conference - PRNewsWire
- 2 months ago - Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Guidance - PRNewsWire
- 2 months ago - Dynavax to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 22, 2024 - PRNewsWire
- 4 months ago - Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Highlights - PRNewsWire
- 4 months ago - Dynavax to Present at the 42nd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 4 months ago - 20 favorite small-cap stocks for 2024 among Wall Street analysts - Market Watch
- 5 months ago - Dynavax to Present at the 6th Annual Evercore ISI HealthCONx Conference - PRNewsWire